Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

8.9%

253 terminated/withdrawn out of 2849 trials

Success Rate

89.6%

+3.1% vs industry average

Late-Stage Pipeline

33%

943 trials in Phase 3/4

Results Transparency

72%

1562 of 2170 completed trials have results

Key Signals

175 recruiting1562 with results207 terminated46 withdrawn

Enrollment Performance

Analytics

Phase 1

948(34.9%)

Phase 2

732(27.0%)

Phase 3

663(24.4%)

Phase 4

280(10.3%)

N/A

84(3.1%)

Early Phase 1

7(0.3%)

2714Total

Phase 1(948)

Phase 2(732)

Phase 3(663)

Phase 4(280)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2849)

Showing 20 of 2849 trials

NCT07223840Phase 2Recruiting

A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse

Role: lead

NCT05063539Phase 2Completed

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

Role: lead

NCT06025747Phase 1Recruiting

A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas

Role: collaborator

NCT06864026Phase 4Recruiting

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Role: lead

NCT07641504Phase 2Not Yet Recruiting

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain

Role: lead

NCT07641517Phase 2Not Yet Recruiting

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain

Role: lead

NCT04607421Phase 3Active Not Recruiting

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Role: collaborator

NCT07412756Phase 3Recruiting

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Role: lead

NCT07640139Enrolling By Invitation

Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes

Role: collaborator

NCT07279688Phase 3Recruiting

Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

Role: collaborator

NCT05767021Phase 3Completed

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Role: lead

NCT05936138Phase 1Completed

A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.

Role: lead

NCT07357415Phase 3Active Not Recruiting

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Role: lead

NCT07519525Phase 1Completed

A Study of [14C]-LY4064809 in Healthy Participants

Role: lead

NCT02846987Phase 2Active Not Recruiting

Study of Abemaciclib in Dedifferentiated Liposarcoma

Role: collaborator

NCT07589608Phase 2Not Yet Recruiting

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Role: lead

NCT07629401Unknown

Provide Pre-approval Expanded Access of LY3437943

Role: lead

NCT06948786Phase 2Recruiting

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Role: collaborator

NCT07169851Phase 2Recruiting

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Role: lead

NCT07282600Phase 3Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Role: lead